Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07510386 · ClinicalTrials.gov registry record · NA
CGM After Discharge From Hospital
A NA study, sponsored by Icahn School of Medicine at Mount Sinai.
- Not yet
- Registry status
- NA
- Development phase
- 64
- Enrollment target
NCT07510386 is a NA study that has not yet begun recruiting, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 64 participants.
The verdict
NCT07510386, a NA study, has not yet begun recruiting, sponsored by Icahn School of Medicine at Mount Sinai.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
Study Summary
This is an investigator initiated prospective, randomized controlled trial which aims to compare two groups of patients with either type 2 or steroid-induced diabetes who are discharged with insulin. The intervention group will use the Libre 3 Plus continuous glucose monitoring (CGM) system at discharge, while the control group will use blinded CGM and fingerstick monitoring. Both the intervention and control groups will wear the sensor for 28 days post discharge and participate in telehealth diabetes management visits. The target enrollment for the study is 65 participants and participants are expected to be in the study for up to 35 days.
Interventions
- DEVICE Libre 3 Plus continuous glucose monitoring (CGM) system
- DEVICE Blinded Continuous Glucose Monitoring
- BEHAVIORAL Finger stick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2026-04 |
| Est. Completion | 2026-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07510386
The ClinicalTrials.gov registry entry for NCT07510386 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Libre 3 Plus continuous glucose monitoring (CGM) system is the first listed.
NCT07510386 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07510386 about?
NCT07510386 is a clinical study titled "CGM After Discharge From Hospital". This is an investigator initiated prospective, randomized controlled trial which aims to compare two groups of patients with either type 2 or steroid-induced diabetes who are discharged with insulin. The intervention group will use the Libre 3 Plus continuous glucose monitoring (CGM) system at disch...
What is the current status of trial NCT07510386?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 64 participants. The study started on 2026-04. Estimated completion is 2026-11.
What interventions are being tested in trial NCT07510386?
The interventions under investigation include: Libre 3 Plus continuous glucose monitoring (CGM) system (DEVICE), Blinded Continuous Glucose Monitoring (DEVICE), Finger stick (BEHAVIORAL).
Who is sponsoring clinical trial NCT07510386?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.